<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924155</url>
  </required_header>
  <id_info>
    <org_study_id>SJSJP002_01</org_study_id>
    <nct_id>NCT02924155</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Day/Multiple Day Dosing, Phase I Clinical Trial to Investigate the Systemic Exposure, Safety and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Korean Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samjin Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samjin Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, single day/multiple day dosing,
      Phase I clinical trial to investigate the systemic exposure, safety and local tolerability of
      SJP002 ophthalmic solution in healthy Korean male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmax after dosing</measure>
    <time_frame>Day 1, Day 7, and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: AUC after dosing</measure>
    <time_frame>Day 1, Day 7, and Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and local tolerability are measured by assessment of ophthalmic symptoms.</measure>
    <time_frame>from screening up to 7 weeks</time_frame>
    <description>Ophthalmic symptoms will include ocular dryness and burning of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and local tolerability are measured by assessment of ophthalmic examination.</measure>
    <time_frame>Screening, 1st and 7th day of post-dose</time_frame>
    <description>Ophthalmic examination will include visual acuity and IOP.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SJP002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single/repeated administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SJP002 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single/repeated administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SJP002</intervention_name>
    <arm_group_label>SJP002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>SJP002 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Korean male 20-50 years old

        Exclusion Criteria:

          -  Present condition or history of any clinically significant disease

          -  History of hypersensitivities, including drug allergies

          -  Present condition or history of following diseases; History of Keratitis, Uveitis,
             Retinitis, or Dry eye syndrome, Corrective sight scale below 20/40(0.5), Present of
             adverse reaction after wearing contact lens or plan to wear contact lens, History of
             ophthalmic surgery.

          -  Drug abuse within 60 days, or a positive reaction to Drug testing in Urine

          -  Taken any ETC of herbal supplement within 14 days or any OTC or vitamin supplement
             within 7 days

          -  Participation in and administration of IP of another clinical trial within 90 days

          -  Donation of whole blood within 60 days or blood components within 30 days, or receipt
             of blood transfusion within 30 days

          -  Consumption of more than 21 units of alcohol/week or inability to abstain from
             drinking during the study period

          -  Smoking within 90 days

          -  Plan to be pregnant, or not to use an appropriate method of contraception
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-sang Yu, M.D., Ph.D., M.B.A.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine / Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-kyung Kim, M.D.</last_name>
    <email>anace8989@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-kyung Kim, M.D.</last_name>
      <email>anace8989@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

